Mitchall Clark, Atara Biotherapeutics, Inc. (ATRA)’s insider Sold 22,400 Shares; Cam Group Holding A Lowered Johnson & Johnson (JNJ) Stake By $641,763

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Logo

Cam Group Holding A decreased Johnson & Johnson (JNJ) stake by 1.51% reported in 2017Q4 SEC filing. Cam Group Holding A sold 4,617 shares as Johnson & Johnson (JNJ)’s stock declined 9.21%. The Cam Group Holding A holds 301,614 shares with $42.14 million value, down from 306,231 last quarter. Johnson & Johnson now has $344.32B valuation. The stock increased 3.04% or $3.79 during the last trading session, reaching $128.35. About 7.98M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 1.12% since April 3, 2017 and is uptrending. It has underperformed by 10.43% the S&P500.

Investors sentiment decreased to 1.42 in 2017 Q4. Its down 0.12, from 1.54 in 2017Q3. It turned negative, as 9 investors sold Atara Biotherapeutics, Inc. shares while 17 reduced holdings. 12 funds opened positions while 25 raised stakes. 27.87 million shares or 6.54% more from 26.16 million shares in 2017Q3 were reported. Northern Corporation owns 288,773 shares. Pacific Heights Asset Mgmt Llc holds 0.04% or 25,000 shares. Alyeska Inv Grp Inc Limited Partnership holds 0.03% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 174,868 shares. Harbourvest Ltd holds 0.15% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 10,543 shares. State Bank Of Montreal Can owns 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 4,591 shares. 5,000 were reported by One Trading Ltd Partnership. New York-based Hudson Bay Cap Management L P has invested 0.01% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). State Street has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 443,821 shares. 398,700 are held by 12 West Mgmt L P. Legal And General Gru Public Ltd Limited Liability Company holds 6,326 shares. Moreover, Dekabank Deutsche Girozentrale has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Parametric Associate Llc, a Washington-based fund reported 42,808 shares. Pnc Financial has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 34 shares. Rhumbline Advisers has invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Artal Group holds 0.27% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 1.00 million shares.

The stock decreased 1.76% or $0.65 during the last trading session, reaching $36.25. About 595,453 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has risen 88.73% since April 3, 2017 and is uptrending. It has outperformed by 77.18% the S&P500.

Among 8 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 have Buy rating, 1 Sell and 3 Hold. Therefore 50% are positive. Atara Biotherapeutics has $80 highest and $8 lowest target. $35.40’s average target is -2.34% below currents $36.25 stock price. Atara Biotherapeutics had 24 analyst reports since September 9, 2015 according to SRatingsIntel. The firm earned “Market Outperform” rating on Tuesday, December 15 by JMP Securities. The firm has “Sell” rating given on Friday, August 19 by Citigroup. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Buy” rating given on Monday, March 5 by Jefferies. The rating was maintained by Canaccord Genuity on Tuesday, January 30 with “Buy”. The firm has “Outperform” rating given on Friday, October 9 by William Blair. JMP Securities initiated the shares of ATRA in report on Friday, September 25 with “Mkt Perform” rating. As per Thursday, June 22, the company rating was reinitiated by Jefferies. Jefferies maintained the shares of ATRA in report on Thursday, August 31 with “Buy” rating. The stock has “Neutral” rating by Citigroup on Wednesday, January 3. The rating was downgraded by Citigroup on Thursday, February 15 to “Sell”.

Since October 11, 2017, it had 0 buys, and 21 sales for $13.49 million activity. The insider MCGRATH JOHN sold $242,460. Turner Heather D sold $464,210 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Friday, February 9. Ciechanover Isaac E. also sold $680,534 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares. Another trade for 1,183 shares valued at $55,010 was sold by Gallagher Carol Giltner. Haqq Christopher also sold $86,100 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares. Clark Mitchall G. had sold 100,203 shares worth $3.80 million.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.56 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

The EVP & Chief R & QA Officer of Atara Biotherapeutics Inc and firm’s insider Mitchall Clark made a sale of 22,400 shares of the Pinksheet-listed Atara Biotherapeutics Inc based on the avg market share price which is $40.1 per share. The transaction’s shares are worth based on the market approximately $897,568 U.S Dollars. He also sold 100,203 shares with a market value $3,795,062 USD in the last 30 days. Due to the size of the transaction there is little probability that it will go hidden. Mitchall Clark presently has in hand 133,671 shares or 0.31% of Atara Biotherapeutics Inc’s market cap.

Analysts await Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report earnings on May, 3. They expect $-0.92 earnings per share, down 4.55% or $0.04 from last year’s $-0.88 per share. After $-1.15 actual earnings per share reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts -20.00% EPS growth.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 11 have Buy rating, 5 Sell and 7 Hold. Therefore 48% are positive. Johnson & Johnson had 92 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Johnson & Johnson (NYSE:JNJ) earned “Sell” rating by BTIG Research on Friday, July 21. Jefferies maintained the stock with “Hold” rating in Thursday, August 4 report. The company was downgraded on Friday, July 21 by Atlantic Securities. On Tuesday, August 25 the stock rating was maintained by Cowen & Co with “Outperform”. The stock of Johnson & Johnson (NYSE:JNJ) earned “Hold” rating by Societe Generale on Wednesday, April 6. UBS maintained the stock with “Buy” rating in Thursday, August 31 report. BMO Capital Markets maintained the shares of JNJ in report on Tuesday, July 18 with “Buy” rating. On Tuesday, July 18 the stock rating was maintained by Stifel Nicolaus with “Hold”. Wells Fargo maintained Johnson & Johnson (NYSE:JNJ) rating on Friday, January 12. Wells Fargo has “Buy” rating and $160.0 target. The stock of Johnson & Johnson (NYSE:JNJ) has “Hold” rating given on Wednesday, January 24 by Stifel Nicolaus.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on April, 17. They expect $2.01 earnings per share, up 9.84% or $0.18 from last year’s $1.83 per share. JNJ’s profit will be $5.39B for 15.96 P/E if the $2.01 EPS becomes a reality. After $1.74 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts 15.52% EPS growth.

Investors sentiment increased to 0.87 in 2017 Q4. Its up 0.04, from 0.83 in 2017Q3. It increased, as 35 investors sold JNJ shares while 884 reduced holdings. 143 funds opened positions while 654 raised stakes. 1.72 billion shares or 0.40% more from 1.71 billion shares in 2017Q3 were reported. Paradigm Asset Communication Limited Liability Company reported 0.22% stake. Fire Grp Inc Incorporated owns 38,000 shares or 1.73% of their US portfolio. Highland Capital Mgmt Limited Partnership reported 0.02% in Johnson & Johnson (NYSE:JNJ). Gulf Int Bank (Uk) Ltd invested in 1.51% or 850,180 shares. Northern holds 1.24% or 35.12M shares. Mercer Cap Advisers invested in 70,240 shares or 7.1% of the stock. Flippin Bruce & Porter Inc has 2.3% invested in Johnson & Johnson (NYSE:JNJ) for 77,361 shares. Hancock Holdg Company reported 0.65% of its portfolio in Johnson & Johnson (NYSE:JNJ). Brandywine Invest Management Limited Liability Company has 2.03% invested in Johnson & Johnson (NYSE:JNJ) for 2.43M shares. Lourd Capital, a California-based fund reported 21,384 shares. Bonness Entertainment holds 3.89% or 41,038 shares. Capital Intll Ltd Ca invested in 1,600 shares. Nikko Asset Mgmt Americas reported 18,300 shares or 0.06% of all its holdings. Perigon Wealth Management Ltd Liability Corp accumulated 34,051 shares or 1.78% of the stock. Tru Department Mb National Bank N A reported 120,440 shares.

Cam Group Holding A increased Amazon Inc (NASDAQ:AMZN) stake by 7,804 shares to 310,405 valued at $363.01 million in 2017Q4. It also upped Dex Inc (NASDAQ:DXCM) stake by 14,852 shares and now owns 71,687 shares. Priceline Grp Inc (NASDAQ:PCLN) was raised too.

Since February 15, 2018, it had 0 buys, and 1 sale for $20.17 million activity. The insider Stoffels Paulus sold 155,342 shares worth $20.17 million.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart